MX2017001096A - Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo. - Google Patents
Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo.Info
- Publication number
- MX2017001096A MX2017001096A MX2017001096A MX2017001096A MX2017001096A MX 2017001096 A MX2017001096 A MX 2017001096A MX 2017001096 A MX2017001096 A MX 2017001096A MX 2017001096 A MX2017001096 A MX 2017001096A MX 2017001096 A MX2017001096 A MX 2017001096A
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- halogen
- lower alkoxy
- lower alkyl
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a compuestos de fórmula (ver Fórmula) en la que L es un enlace, -C(O)NH-, -NHC(O)-, -CH2NHC(O)-, CH2C(O)NH-, -CH2NH-, -NH- o -NHC (O) NH-; R1 es hidrógeno, alquilo inferior, halógeno, alcoxi inferior-alquilo, alcoxi inferior sustituido con halógeno, alquilo inferior sustituido con halógeno o es fenilo o heteroarilo seleccionado entre el grupo que consiste en piridinilo, pirimidinilo, pirazinilo o pirazolilo, y en el que el fenilo y el heteroarilo están opcionalmente sustituidos con uno, dos o tres sustituyentes seleccionados entre el grupo que consiste en halógeno, alquilo inferior, alcoxi inferior, alquilo inferior sustituido con halógeno, alcoxi inferior sustituido con halógeno, cicloalquilo o O-CH2- cicloalquilo; o a una sal de adición de ácidos farmacéuticamente aceptable de los mismos, a todas las mezclas racémicas, a todos sus enantiómeros correspondientes y/o isómeros ópticos, que puede usarse para el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, trastorno de déficit de atención e hiperactividad (TDAH), trastornos relacionados con el estrés, trastornos psicóticos, esquizofrenia, enfermedades neurológicas, enfermedad de Parkinson, trastornos neurodegenerativos, enfermedad de Alzheimer, epilepsia, migraña, hipertensión, abuso de sustancias, trastornos metabólicos, trastornos alimentarios, diabetes, complicaciones diabéticas, obesidad, dislipidemia, trastornos de consumo y asimilación de energía, trastornos de mal funcionamiento de la homeostasis de la temperatura corporal, trastornos del sueño y del ritmo circadiano, y trastornos cardiovasculares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2014/083549 WO2016015333A1 (en) | 2014-08-01 | 2014-08-01 | 2-oxa-5-azabicyclo [2.2.1] heptan-3-yl derivatives |
PCT/EP2015/067353 WO2016016292A1 (en) | 2014-08-01 | 2015-07-29 | 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017001096A true MX2017001096A (es) | 2017-04-27 |
Family
ID=53758230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017001096A MX2017001096A (es) | 2014-08-01 | 2015-07-29 | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo. |
Country Status (11)
Country | Link |
---|---|
US (1) | US9790230B2 (es) |
EP (1) | EP3174886B1 (es) |
JP (1) | JP6364121B2 (es) |
KR (1) | KR101911651B1 (es) |
CN (1) | CN106661043B (es) |
AR (1) | AR101359A1 (es) |
CA (1) | CA2954209C (es) |
MX (1) | MX2017001096A (es) |
RU (1) | RU2697651C2 (es) |
TW (1) | TWI583687B (es) |
WO (2) | WO2016015333A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017234042B2 (en) * | 2016-03-17 | 2020-11-19 | F. Hoffmann-La Roche Ag | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of TAAR |
EP3463359A4 (en) * | 2016-06-02 | 2020-08-26 | Purdue Pharma LP | SPURENAMINE-ASSOCIATED RECEPTOR-1 AGONISTS AND PARTIAL AGONISTS FOR PAIN MANAGEMENT |
CN106187911A (zh) * | 2016-07-04 | 2016-12-07 | 烟台凯博医药科技有限公司 | 2‑三氟甲基嘧啶‑4‑羧酸及其衍生物和制备方法 |
US20230416199A1 (en) * | 2020-10-23 | 2023-12-28 | Icahn School Of Medicine At Mount Sinai | Inhibitors of amino acid transport |
WO2023033681A1 (en) | 2021-09-01 | 2023-03-09 | Limited Liability Company «Excellena Research And Development» (Llc «Excellena») | Substituted 2-(5-aryl-4 h-1,2,4-triazol-3-yl)ethanamines as modulators of trace amine-associated receptor 1 (taar1) |
WO2023033679A1 (en) * | 2021-09-01 | 2023-03-09 | Limited Liability Company «Excellena Research And Development» (Llc «Excellena») | (azacycloalkyl)methoxy-substituted benzamides as modulators of trace amine-associated receptor 1 (taar1) |
WO2023033680A1 (en) | 2021-09-01 | 2023-03-09 | Limited Liability Company «Excellena Research And Development» (Llc «Excellena») | Substituted 2,3,4,5-tetrahydrobenzo[ f][1,4]oxazepines as modulators of trace amine-associated receptor 1 (taar1) |
WO2023156565A1 (en) * | 2022-02-16 | 2023-08-24 | Awakn Ls Europe Holdings Limited | Bridged ring compounds and their therapeutic use as cns agents |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3431257A1 (de) * | 1984-08-24 | 1986-03-06 | Bayer Ag, 5090 Leverkusen | Neue (delta)-butyrolactame, pharmakologisch aktive zusammensetzungen derselben, verfahren zu ihrer herstellung und ihre medizinische verwendung |
CN1012172B (zh) * | 1984-08-24 | 1991-03-27 | 北京医学科学院药物研究所 | 新型黄皮酰胺类化合物的分离和提取方法 |
DE3927369A1 (de) * | 1989-08-19 | 1991-02-21 | Bayer Ag | Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe |
FR2912404B1 (fr) * | 2007-02-09 | 2009-04-10 | Sanofi Aventis Sa | Derives d'azabicycloalkane,leur preparation et leur application en therapeutique. |
US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
WO2014072257A1 (en) * | 2012-11-07 | 2014-05-15 | F. Hoffmann-La Roche Ag | Pyrazine derivatives |
HUE039262T2 (hu) * | 2014-05-28 | 2018-12-28 | Hoffmann La Roche | 5-oxa-2-azabiciklo [2.2.2] oktán-4-il- és 5-oxa-2-azabiciklo [2.2.1] heptán-4-il-származékok TAAR1 modulátorokként |
-
2014
- 2014-08-01 WO PCT/CN2014/083549 patent/WO2016015333A1/en active Application Filing
-
2015
- 2015-07-28 TW TW104124431A patent/TWI583687B/zh active
- 2015-07-29 AR ARP150102417A patent/AR101359A1/es active IP Right Grant
- 2015-07-29 EP EP15742309.6A patent/EP3174886B1/en active Active
- 2015-07-29 CN CN201580035802.9A patent/CN106661043B/zh active Active
- 2015-07-29 WO PCT/EP2015/067353 patent/WO2016016292A1/en active Application Filing
- 2015-07-29 JP JP2017505442A patent/JP6364121B2/ja active Active
- 2015-07-29 RU RU2017104264A patent/RU2697651C2/ru active
- 2015-07-29 MX MX2017001096A patent/MX2017001096A/es unknown
- 2015-07-29 KR KR1020177002662A patent/KR101911651B1/ko active IP Right Grant
- 2015-07-29 CA CA2954209A patent/CA2954209C/en active Active
-
2017
- 2017-01-26 US US15/416,485 patent/US9790230B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
RU2017104264A3 (es) | 2019-02-27 |
EP3174886A1 (en) | 2017-06-07 |
JP2017522353A (ja) | 2017-08-10 |
CA2954209A1 (en) | 2016-02-04 |
EP3174886B1 (en) | 2021-02-17 |
BR112016028714A2 (pt) | 2017-08-22 |
WO2016015333A1 (en) | 2016-02-04 |
JP6364121B2 (ja) | 2018-07-25 |
TW201617349A (zh) | 2016-05-16 |
US9790230B2 (en) | 2017-10-17 |
US20170137435A1 (en) | 2017-05-18 |
RU2017104264A (ru) | 2018-09-04 |
TWI583687B (zh) | 2017-05-21 |
AR101359A1 (es) | 2016-12-14 |
CN106661043A (zh) | 2017-05-10 |
KR101911651B1 (ko) | 2018-10-24 |
WO2016016292A1 (en) | 2016-02-04 |
RU2697651C2 (ru) | 2019-08-16 |
KR20170021352A (ko) | 2017-02-27 |
CA2954209C (en) | 2022-08-30 |
CN106661043B (zh) | 2020-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017001096A (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo. | |
MX351918B (es) | Derivados heterociclicos de amina. | |
TW200738645A (en) | Use of 4-imidazole derivatives for CNS disorders | |
MY162160A (en) | Pyrazole derivatives | |
MY176030A (en) | Substituted benzamide derivatives | |
MX354815B (es) | Derivados heterociclicos como receptores asociados con las aminas traza (taars). | |
UA98951C2 (ru) | 2-аминооксазолины и лекарственное средство, которое их содержит | |
TW200833685A (en) | Aminomethyl-4-imidazoles | |
MX2016013412A (es) | Derivados de morfolina-piridina. | |
MX2016016488A (es) | Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar). | |
MY162461A (en) | Substituted benzamide derivatives | |
MX2015014353A (es) | Derivados de 2-fenil- o 2-hetaril-imidazol[1,2-a]piridina. | |
MX2016008536A (es) | Derivados de fluoro-naftilo. | |
TW200738690A (en) | Use of 2-imidazoles for the treatment of CNS disorders | |
MX2016002717A (es) | Derivado de etinilo. | |
MX361761B (es) | Derivados de triazol carboxamida. | |
MX2015005721A (es) | Derivados de pirazina. | |
MX2009005920A (es) | Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina. | |
MX2016016606A (es) | Derivados de 6-amino-5,6,7,8-tetrahidronaftalen-2-ilo o de 3-aminocroman-7-ilo como moduladores de receptores asociados a aminastraza (taar). | |
UA113776C2 (xx) | Похідні піразолкарбоксаміду як модулятори рецепторів слідових амінів (taar) для застосування при лікуванні різних розладів, таких як депресія, діабет та хвороба паркінсона | |
MX2016012624A (es) | Derivados de 5-oxa-2-azabiciclo[2.2.2]octan-4-ilo y 5-oxa-2-azabiciclo[2.2.1]heptan-4-ilo como modularores de los receptores asociados a la amina de trazas 1 (taar1). | |
MX349738B (es) | Derivados de dihidrooxazol-2-amina. | |
AR076979A1 (es) | 2- aminooxazolinas como ligandos de taar1 | |
MX2016016190A (es) | Derivados de pirazino[2,1-a]isoquinolina sustituida para el tratamiento de trastornos del sistema nervioso central. |